KR20150010973A - 피라졸 유도체 및 lpar5 길항제로서의 그의 용도 - Google Patents

피라졸 유도체 및 lpar5 길항제로서의 그의 용도 Download PDF

Info

Publication number
KR20150010973A
KR20150010973A KR20147033843A KR20147033843A KR20150010973A KR 20150010973 A KR20150010973 A KR 20150010973A KR 20147033843 A KR20147033843 A KR 20147033843A KR 20147033843 A KR20147033843 A KR 20147033843A KR 20150010973 A KR20150010973 A KR 20150010973A
Authority
KR
South Korea
Prior art keywords
alkyl
group
phenyl
methyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147033843A
Other languages
English (en)
Korean (ko)
Inventor
마르크 나자레
데틀레프 코지안
안드레아스 에베르스
베른가르트 체흐티즈키
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20150010973A publication Critical patent/KR20150010973A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR20147033843A 2012-05-18 2013-05-16 피라졸 유도체 및 lpar5 길항제로서의 그의 용도 Ceased KR20150010973A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305552 2012-05-18
EP12305552.7 2012-05-18
PCT/EP2013/060171 WO2013171317A1 (en) 2012-05-18 2013-05-16 Pyrazole derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
KR20150010973A true KR20150010973A (ko) 2015-01-29

Family

ID=48446368

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147033843A Ceased KR20150010973A (ko) 2012-05-18 2013-05-16 피라졸 유도체 및 lpar5 길항제로서의 그의 용도

Country Status (22)

Country Link
US (1) US9346762B2 (enExample)
EP (1) EP2882715B1 (enExample)
JP (1) JP6257596B2 (enExample)
KR (1) KR20150010973A (enExample)
CN (1) CN104302625B (enExample)
AU (1) AU2013261718B2 (enExample)
BR (1) BR112014028406A2 (enExample)
CA (1) CA2871542A1 (enExample)
CY (1) CY1118618T1 (enExample)
DK (1) DK2882715T3 (enExample)
ES (1) ES2612205T3 (enExample)
HR (1) HRP20170098T1 (enExample)
HU (1) HUE032890T2 (enExample)
IL (1) IL235221A (enExample)
LT (1) LT2882715T (enExample)
MX (1) MX347615B (enExample)
PL (1) PL2882715T3 (enExample)
PT (1) PT2882715T (enExample)
RU (1) RU2645344C2 (enExample)
SG (1) SG11201407210SA (enExample)
SI (1) SI2882715T1 (enExample)
WO (1) WO2013171317A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171316A1 (en) 2012-05-18 2013-11-21 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
WO2016201426A1 (en) 2015-06-12 2016-12-15 Vettore, LLC Mct4 inhibitors for treating disease
DK3551625T3 (da) * 2016-12-12 2024-09-02 Vettore Llc Heterocykliske inhibitorer af mct4
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease
CN119930520A (zh) * 2023-11-03 2025-05-06 中国药科大学 N-芳基吡唑类化合物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
JP4505329B2 (ja) 2002-09-04 2010-07-21 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
KR20090106660A (ko) 2007-02-09 2009-10-09 다케다 야쿠힌 고교 가부시키가이샤 Ｐｐａｒ-감마의 부분 작용제로서의 축합 고리 화합물
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
BRPI0907977A2 (pt) * 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
JP5509100B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用
US20120010241A1 (en) * 2009-03-19 2012-01-12 Sanofi Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof
US8350052B2 (en) * 2009-08-03 2013-01-08 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required magnesium intermediates
JP6039559B2 (ja) * 2010-09-02 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体
WO2013171316A1 (en) 2012-05-18 2013-11-21 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation

Also Published As

Publication number Publication date
SG11201407210SA (en) 2014-12-30
IL235221A (en) 2016-06-30
US9346762B2 (en) 2016-05-24
RU2014151360A (ru) 2016-07-10
BR112014028406A2 (pt) 2017-06-27
SI2882715T1 (sl) 2017-03-31
CN104302625B (zh) 2017-04-19
AU2013261718B2 (en) 2017-10-19
MX347615B (es) 2017-05-04
WO2013171317A1 (en) 2013-11-21
JP2015517514A (ja) 2015-06-22
AU2013261718A1 (en) 2014-12-18
CN104302625A (zh) 2015-01-21
EP2882715A1 (en) 2015-06-17
LT2882715T (lt) 2017-02-10
RU2645344C2 (ru) 2018-02-21
CA2871542A1 (en) 2013-11-21
PL2882715T3 (pl) 2017-04-28
HUE032890T2 (hu) 2017-11-28
JP6257596B2 (ja) 2018-01-10
HRP20170098T1 (hr) 2017-03-24
MX2014014011A (es) 2015-02-12
EP2882715B1 (en) 2016-11-09
CY1118618T1 (el) 2017-07-12
PT2882715T (pt) 2016-12-30
DK2882715T3 (en) 2017-02-13
ES2612205T3 (es) 2017-05-12
US20150141477A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CN116082303B (zh) 新型氧代吡啶类化合物及其中间体和应用
JP6884801B2 (ja) 血漿カリクレインインヒビターとしてのピラゾール誘導体
KR101589332B1 (ko) ２ｈ-크로멘 화합물 및 그의 유도체
KR20170090451A (ko) 혈장 칼리크레인의 저해제로서의 n-((het)아릴메틸)-헤테로아릴-카르복사미드 화합물
HK1214247A1 (zh) 作為細胞凋亡信號調節激酶抑制劑的經取代的吡啶-2-甲酰胺化合物
EA015942B1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
KR20150010973A (ko) 피라졸 유도체 및 lpar5 길항제로서의 그의 용도
JP7617165B2 (ja) 炎症性気道疾患の治療のためのオートタキシン（ａｔｘ）モジュレーターとしての１－（６－（メトキシ）ピリダジン－３－イル）シクロプロパン－１－カルボキサミド誘導体
JP2001527042A (ja) ナトリウム／プロトン交換アシルグアニジン抑制剤および方法
KR102832446B1 (ko) 피리미딘계 화합물 및 그 제조 방법
CN105209440B (zh) 作为凝血酶抑制剂的卤代吡唑
JP2022527618A (ja) Ｔｒｐｃ６阻害剤
EP2850062B1 (en) Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
KR20150016304A (ko) 벤조[1,3]디옥신 유도체 및 lpar5 길항제로서의 그의 용도
TW202235078A (zh) 自分泌運動因子（ａｕｔｏｔａｘｉｎ）之新穎的抑制劑
JP2011503022A (ja) レニン阻害剤としての４，４−二置換ピペリジン
JP2006298909A (ja) 医薬組成物
JP7458984B2 (ja) テトラヒドロイソキノリン系誘導体、その製造方法及び用途
WO2019144811A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
EA042646B1 (ru) Пиридазины
JP2006516127A (ja) ホスホジエステラーゼ４阻害剤としてのフタラジン誘導体
KR20130131775A (ko) 인자 ＸＩａ 억제 활성을 갖는 다이펩타이드 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180516

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190812

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190812

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I